COMP360 Psilocybin NDA Filed: What Compass Needs for a 2027 Launch
Compass Pathways has completed its COMP360 psilocybin NDA for treatment-resistant depression. Here is the Phase 3 data, the voucher timeline and the DEA hurdle.
Compass Pathways has completed its COMP360 psilocybin NDA for treatment-resistant depression. Here is the Phase 3 data, the voucher timeline and the DEA hurdle.